MGB-SCAR

The primary aims of a study known as Massachusetts General Brigham-Severe Cutaneous Adverse Reaction (MGB-SCAR) are to learn more about who is at increased risk for severe cutaneous adverse reactions (SCARs) in the United States and to study the immediate and long-term consequences of SCARs on health and quality of life. MGB-SCAR is led by Dr. Li Zhou and affiliated with the Division of General Internal Medicine and Primary Care at Brigham and Women’s Hospital and the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital.  

Under the leadership of Dr. Elizabeth Phillips, CDSI research personnel are processing saliva samples to help determine the clinical and genetic factors that increase an individual’s risk for SCARs. The identification of drug and patient-specific factors that lead to drug hypersensitivity is a specific aim of MGB-SCAR and CDSI. 

More about the study 

Please visit MGB-SCAR for more information on the study, including who may participate and the tasks associated with participation.  

Questions? 

If you have any questions about the study, please get in touch with MGB-SCAR at scarmterms@bwh.harvard.edu or (857) 292-4088.